Grants Search Results

Diffuse midline glioma is a devastating disease with no known curative therapy. New treatments using immunotherapy approaches, like CAR T therapy, show promise; however, tumors often escape detection by hiding their target proteins and suppressing the immune response to therapy. Dr. Pomaville seeks to tackle this problem by manipulating RNA modifications in the tumor and body to improve response to CAR T therapy. She has found that drugs that mediate RNA methylation, the most common modification on protein-coding mRNA, increases protein levels of existing CAR T antigens and can induce cell death. This RNA modification mark also influences how the body's immune system responds to tumors. Dr. Pomaville will test this drug in cell-line and immunocompetent models to assess whether manipulation of RNA methylation leads to improved efficacy of CAR T therapy. Dr. Pomaville and team will develop combination strategies that enhance the response to immunotherapy in patients.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

Dr. Kagami is developing LBSeq4Kids, a novel liquid biopsy test designed specifically for children with cancer. Traditional biopsies are invasive and only provide information from one point in time. In contrast, liquid biopsies use samples of body fluids - such as blood, spinal fluid, or fluid from the eye - to detect tumor DNA in real time. While this method is used in adult cancers, it is not widely available for children due to smaller sample volumes and the genetic variety of tumors. Dr. Kagami and colleagues are developing and clinically validating a three-part testing platform. LBSeq4Kids will help to better personalize treatment and monitor how a child's cancer responds to therapy. This project will also help determine which liquid biopsy tests and body fluids provide the most useful information for different cancers and stages of treatment. The goal is to improve diagnosis, guide more effective targeted therapies, and support better long-term outcomes for children with cancer.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

In some children with cancer, their bodies become severely inflamed and they develop a condition known as hemophagocytic lymphohistiocytosis, or HLH, which is often deadly. It is not yet understood why some children with cancer develop HLH and others do not. Dr. Meyer is using advanced technologies to carefully study blood cells from children with cancer who develop HLH. She is also working to create the first model of this disease so that she can better study the underlying disease mechanisms. By increasing our understanding of HLH, she seeks to develop strategies that will help doctors quickly identify affected children and determine which medicines are most effective. Her overall goal is to help more children survive this devastating condition. If successful, her findings will apply not only to HLH, but also to other life-threatening immune system disorders resulting from cancer and/or its treatment.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

Acute myeloid leukemia (AML) is an aggressive and molecularly heterogeneous cancer. Despite recent progress in developing new agents, front-line therapeutic protocols have not changed markedly over the past two decades and are associated with substantial morbidity and mortality. Accordingly, there is a need to develop novel mechanism-based treatments. Pediatric AML patients with NUP98 (nuclear pore complex protein 98) gene rearrangements (NUP98-r) have particularly dismal outcomes, with overall survival rates of 25-35%. Dr. Tian and colleagues are studying important proteins that contribute to a cell's ability to become cancerous in one of the most common types of NUP98-r AML: NUP98::KDM5A. Dr. Tian is also optimizing a compound's ability to directly inhibit KDM5A. Identification of these targets will allow for development of new drugs in the treatment of NUP98-r pediatric AML.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

The survival rates for children with cancer remains unacceptable and the treatments for childhood cancers continue to carry significant life-altering side effects as most treatments do not specifically recognize cancer cells and affect healthy cells. Dr. Guerra and colleagues are developing a therapy created from the white blood cells of a patient's own immune system, known as immunotherapy. These cells are engineered to target cancer cells by engaging a marker that is present on the surface of cancer cells but not present on healthy cells. When the engineered white blood cells engage this cancer-specific marker, the cells become activated and attack the cancer cells while sparing healthy cells. Additionally, this immunotherapy can be boosted with further engineering approaches to remain active in a patient for long periods of time, allowing for long-term killing of cancer cells which we predict will improve survival while reducing treatment-related side effects.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

Relapsed/refractory pediatric acute myeloid leukemia (AML) is a challenging disease with poor survival. Combining two classes of drugs--thalidomide analogs (TAs) and menin inhibitors- may improve outcomes for patients with a particular genetic subtype of AML. Dr. Li has shown that TAs can affect the numbers and activity of a type of immune cell called regulatory T cells (Treg), which can prevent the immune system from recognizing and attacking leukemia cells. Treating pediatric AML patients with TAs and menin inhibitor, which is being tested in an upcoming clinical trial, may impair Treg activity and improve immune recognition and targeting of AML, potentially contributing to responses. Dr. Li will study the effects of combination therapy on models. Dr. Li's study will improve the efficacy and safety of new pediatric AML therapies by defining their effects on immune responses.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Orlando Health Arnold Palmer Hospital for Children's goal is to work towards providing personalized medicine to improve cancer outcomes for children. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Children's Hospital of The King's Daughters (CHKD) cares for children diagnosed with cancer in southeast Virginia and northeast North Carolina. Clinical trials at CHKD allow for children throughout their great region to access novel agents without traveling far from home. This grant supports the Clinical Research Team to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Louisiana State University Health Sciences Center and Manning Family Children's is committed to improving outcomes during and after cancer treatment. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Oklahoma Children's has joined the Beat Childhood Cancer Research Consortium, a group of 50+ hospitals that work together to develop new treatments towards treating pediatric cancer. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Golisano Children's Hospital is committed to providing excellent care to all children, adolescents and young adults who are being treated or have been treated with cancer in their region. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports funding towards positions to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The Center for Cancer and Blood Disorders at Phoenix Children's offers early-phase clinical trials for children with cancer, enabling patients to receive the newest, most promising treatments available. This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The UIC/Rush/Stroger Medical Center Children's Oncology Group Program offers pediatric patients the opportunity to enroll onto COG clinical trials, offering cutting edge treatment, optimal care, and comprehensive follow-up. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.